Esthesioneuroblastoma: The Princess Margaret Hospital experience

Head Neck. 2008 Dec;30(12):1607-14. doi: 10.1002/hed.20920.

Abstract

Background: Esthesioneuroblastoma is rare. The aim of the study was to review our experience and to evaluate the staging system and treatment that best correlates with the patient outcome.

Methods: Thirty-nine patients were identified between 1972 and 2006.

Results: At presentation 10% had cervical metastases. None had distant metastasis. Five were treated with surgery, 2 with chemotherapy, 1 with radiotherapy, and 30 with surgery and radiation. Local disease control was 82.6% at 5 years. Recurrence was seen in 33% with local and regional disease recurrence at 15% and 18%, respectively. The 5- and 10-year overall survival rates were 87.9% and 69.2%, respectively. Dulguerov classification correlated most closely to survival and recurrence.

Conclusions: Dulguerov classification best correlates with the patient's outcome. A combined approach is the preferred treatment. It makes no difference whether radiotherapy is given pre or postsurgical resection. Recurrence can occur even 15 years after treatment. Therefore, long-term follow-up is essential.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Esthesioneuroblastoma, Olfactory / pathology
  • Esthesioneuroblastoma, Olfactory / therapy*
  • Female
  • Follow-Up Studies
  • Hospitals, University
  • Humans
  • Male
  • Middle Aged
  • Nasal Cavity*
  • Neck Dissection
  • Neoplasm Recurrence, Local / pathology
  • Neoplasm Recurrence, Local / therapy*
  • Neoplasm Staging
  • Nose Neoplasms / pathology
  • Nose Neoplasms / therapy*
  • Ontario
  • Retrospective Studies
  • Survival Analysis
  • Treatment Outcome